Compare IRON & HOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IRON | HOG |
|---|---|---|
| Founded | 2017 | 1903 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Motor Vehicles |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.3B |
| IPO Year | N/A | N/A |
| Metric | IRON | HOG |
|---|---|---|
| Price | $94.29 | $22.64 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 12 | 7 |
| Target Price | ★ $108.83 | $28.00 |
| AVG Volume (30 Days) | 533.0K | ★ 2.2M |
| Earning Date | 11-06-2025 | 11-04-2025 |
| Dividend Yield | N/A | ★ 3.08% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 4.04 |
| Revenue | N/A | ★ $4,664,627,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $2.04 |
| P/E Ratio | ★ N/A | $5.78 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $30.82 | $20.45 |
| 52 Week High | $97.12 | $34.09 |
| Indicator | IRON | HOG |
|---|---|---|
| Relative Strength Index (RSI) | 62.96 | 32.21 |
| Support Level | $87.18 | $23.62 |
| Resistance Level | $96.18 | $24.98 |
| Average True Range (ATR) | 3.94 | 0.79 |
| MACD | -0.32 | 0.01 |
| Stochastic Oscillator | 56.25 | 15.84 |
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.
Harley-Davidson is a leading global manufacturer of heavyweight motorcycles across the custom, cruising, and touring segments, as well as related merchandise, parts, and accessories. In recent years, the firm has expanded into the adventure touring market with its Pan America model and into electric with the LiveWire brand. Its captive finance arm, Harley-Davidson Financial Services, provides wholesale financing to dealers and retail financing and insurance brokerage services to customers. Harley captured around 37% of the heavyweight domestic market in 2024.